LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression And
Author Manuscript Published OnlineFirst on September 15, 2017; DOI: 10.1158/0008-5472.CAN-17-0496 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression Yi Liang1*, Musaddeque Ahmed1*, Haiyang Guo1, Fraser Soares1, Junjie T. Hua1,2, Shuai Gao3, Catherine Lu1, Christine Poon1, Wanting Han3, Jens Langstein1,4, Muhammad B. Ekram5-7, Brian Li1, Elai Davicioni8, Mandeep Takhar8, Nicholas Erho8, R. Jeffrey Karnes9, Dianne Chadwick10, Theodorus van der Kwast11, Paul C. Boutros2,12,13, Cheryl H. Arrowsmith1,14, Felix Y. Feng15,16,17,18, Anthony M. Joshua1,19, Amina Zoubeidi20, Changmeng Cai3, Housheng H. He1,2 1 Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada; 2 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 3 Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts 02125, USA; 4 German Cancer Research Center, DKFZ, Heidelberg, Germany; 5 Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA, USA; 6 Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA; 7 Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; 8 Research & Development, GenomeDx Biosciences Inc., Vancouver BC, Canada; 9 Department of Urology, Mayo Clinic, Rochester, Minnesota, USA; 10 UHN Program in BioSpecimen Sciences, Department of Pathology, University Health Network, Toronto, Ontario M5G 2C4, Canada; 11 Department of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, Canada; 12 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; 13 Department 1 Downloaded from cancerres.aacrjournals.org on September 27, 2021.
[Show full text]